- Home
- TOPP vs NRXP Comparison
TOPP vs NRXP Comparison
Compare TOPP & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPP
- NRXP
- Stock Information
- Founded
- TOPP 2014
- NRXP 2015
- Country
- TOPP United States
- NRXP United States
- Employees
- TOPP N/A
- NRXP N/A
- Industry
- TOPP
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- TOPP
- NRXP Health Care
- Exchange
- TOPP NYSE
- NRXP Nasdaq
- Market Cap
- TOPP 26.6M
- NRXP 32.6M
- IPO Year
- TOPP 2025
- NRXP N/A
- Fundamental
- Price
- TOPP $1.69
- NRXP $3.27
- Analyst Decision
- TOPP
- NRXP Strong Buy
- Analyst Count
- TOPP 0
- NRXP 4
- Target Price
- TOPP N/A
- NRXP $28.50
- AVG Volume (30 Days)
- TOPP 7.7K
- NRXP 215.7K
- Earning Date
- TOPP 08-11-2025
- NRXP 08-13-2025
- Dividend Yield
- TOPP N/A
- NRXP N/A
- EPS Growth
- TOPP N/A
- NRXP N/A
- EPS
- TOPP N/A
- NRXP N/A
- Revenue
- TOPP $16,117,227.00
- NRXP N/A
- Revenue This Year
- TOPP N/A
- NRXP N/A
- Revenue Next Year
- TOPP N/A
- NRXP N/A
- P/E Ratio
- TOPP N/A
- NRXP N/A
- Revenue Growth
- TOPP 0.44
- NRXP N/A
- 52 Week Low
- TOPP $0.97
- NRXP $1.10
- 52 Week High
- TOPP $4.50
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- TOPP N/A
- NRXP 53.62
- Support Level
- TOPP N/A
- NRXP $2.90
- Resistance Level
- TOPP N/A
- NRXP $3.53
- Average True Range (ATR)
- TOPP 0.00
- NRXP 0.20
- MACD
- TOPP 0.00
- NRXP -0.04
- Stochastic Oscillator
- TOPP 0.00
- NRXP 58.73
About TOPP TOPPOINT HOLDINGS INC
Toppoint Holdings Inc is a truckload services and solutions provider focused on the recycling export supply chain. The company operates in one operating segment where it derives its revenues from the delivery of truckload services.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.